WO2014132327A1 - 血液成分分離装置 - Google Patents
血液成分分離装置 Download PDFInfo
- Publication number
- WO2014132327A1 WO2014132327A1 PCT/JP2013/054881 JP2013054881W WO2014132327A1 WO 2014132327 A1 WO2014132327 A1 WO 2014132327A1 JP 2013054881 W JP2013054881 W JP 2013054881W WO 2014132327 A1 WO2014132327 A1 WO 2014132327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- blood component
- tube
- platelet
- valve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B13/00—Control arrangements specially designed for centrifuges; Programme control of centrifuges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3607—Regulation parameters
- A61M1/3609—Physical characteristics of the blood, e.g. haematocrit, urea
Definitions
- the present invention relates to a blood component separation device for collecting a predetermined blood component from blood.
- component blood collection is performed in which only the platelet liquid or the like is mainly collected and the other components are returned to the blood donor.
- a blood component separation apparatus equipped with a centrifuge is used.
- Patent Document 1 discloses a hematocrit value of blood. It is not specifically disclosed to adjust the extracorporeal circulation amount in consideration of the above.
- the target extracorporeal circulation amount per cycle in the platelet fluid sampling operation was calculated based on the hematocrit value (40%) measured by the blood cell test device, Suppose that it became 450 ml. However, since the actual hematocrit value is 45% and there is an error from the hematocrit value measured by the blood cell test apparatus, it is assumed that the actual extracorporeal circulation amount per cycle is 400 ml. Then, since the actual amount of extracorporeal circulation has decreased more than the target amount of extracorporeal circulation, the concentration of the collected platelet liquid may be smaller than the target concentration (unit breakage of platelets).
- the concentration of the collected platelet fluid may be higher than the target concentration (increase in platelet units). is there.
- the present invention has been made to solve the above-described problems, and an object thereof is to provide a blood component separation device that can collect a predetermined blood component of a target concentration regardless of the measurement accuracy of the blood cell test device. To do.
- One aspect of the present invention made to solve the above problems includes a centrifuge for separating a plurality of predetermined blood components from blood, and a container for storing the centrifuged predetermined blood components.
- a centrifuge for separating a plurality of predetermined blood components from blood
- a container for storing the centrifuged predetermined blood components.
- a predicted extracorporeal circulation volume that is predicted as a target blood collection amount per cycle in the sampling operation of the predetermined blood component
- Computation means for calculating based on the hematocrit value after correcting the measured value of the hematocrit value measured by the apparatus (blood cell counter), and the computation means is used when performing the correction.
- the correction value includes the data value of the predicted extracorporeal circulation amount in the most recent sampling operation for which the sampling operation has already been completed and the data value in the most recent sampling operation. It is calculated based on the data value of the amount of collected blood, which is measured by cycle, characterized by.
- the correction value for the measured value of the hematocrit value is calculated based on the data values in the plurality of predetermined blood component sampling operations that have been completed immediately before the predetermined blood component sampling operation is completed.
- the measured value of the hematocrit value is corrected by the corrected value, and the predicted extracorporeal circulation amount in the current sampling operation is calculated.
- the measurement value of the hematocrit value measured by the blood cell inspection device is corrected, so that a predetermined blood component having a target concentration can be collected even if the measurement accuracy of the blood cell inspection device is low.
- the correction value for the measurement value of the hematocrit value is updated every time one sampling operation is completed, the correction for the measurement value of the hematocrit value can be performed in response to a change in the measurement accuracy of the blood cell test apparatus. . Therefore, a predetermined blood component having a target concentration can be collected regardless of the measurement accuracy of the hematocrit value by the blood cell test apparatus.
- the data value of the predicted extracorporeal circulation amount and the data value of the blood collection amount actually measured in the first cycle are obtained when the blood collection is stopped halfway before the collection operation is completed. It is preferably created by deleting the data value.
- the correction value for the measured value of the hematocrit value is calculated by citing only the data value in the sampling operation in which the predetermined blood component can be sampled.
- centrifuge process which introduce
- said centrifuge A circulating flow step of introducing a first blood component of the predetermined blood components separated by separation together with whole blood into the centrifuge; c) a predetermined amount of the first blood component in the circulating flow step; After separating blood components, stopping the supply of whole blood to the centrifuge, introducing only the first blood component into the centrifuge, further circulating for a predetermined time, and then accelerating the circulation rate A circulation / acceleration step in which the second blood component is separated and collected by the centrifuge, and d) a blood component that has not been collected after collecting a predetermined amount of the second blood component in the circulation / acceleration step About blood return process to return blood to donor It has the a) as step one cycle of ⁇ d), to perform a plurality of times the cycle is
- a predetermined blood component can be accurately separated from other blood components.
- the circulation / acceleration step includes a first collection step of transferring a low-concentration second blood component of the second blood component to the temporary storage container, and a second blood component.
- a second collection step of collecting a second blood component having a high concentration, and the second blood component having a low concentration transferred to the temporary storage container is a whole blood collected in the next cycle. It is preferable to be introduced into the centrifuge together with the above.
- the predetermined blood component is preferably platelet fluid.
- a predetermined blood component having a target concentration can be collected regardless of the measurement accuracy of the blood cell test device.
- FIG. It is a figure which shows the structure of the blood component separation apparatus of Example 1.
- FIG. It is a block diagram which shows the control system of the blood component separation apparatus which concerns on embodiment. It is a figure which shows the structure of a centrifuge bowl.
- 3 is a flowchart illustrating the operation of the blood component separation device according to the first embodiment. It is a flowchart which shows the effect
- FIG. It is a figure which shows a 2nd process (centrifugation process). It is a figure which shows a 3rd process (critical flow process).
- FIG. 6 is a flowchart illustrating the operation of the blood component separation device according to the second embodiment. It is a figure which shows the blood collection process of the blood component separation apparatus of Example 2. FIG. It is a figure which shows the circulation process of the blood component separation apparatus of Example 2. FIG. It is a figure which shows PC collection process of the blood component separation apparatus of Example 2.
- FIG. 1 shows the system configuration of the blood component separation device according to the first embodiment.
- FIG. 2 is a block diagram illustrating a control system of the blood component separation device according to the embodiment.
- the blood component separation device includes a blood component separation circuit 1.
- the blood component separation circuit 1 has a primary blood collection circuit 5 including a blood collection needle 2, a primary blood collection bag Y7 for collecting primary blood, a sampling port 3, and a primary blood collection line 4.
- the blood component separation circuit 1 has a centrifuge bowl E1.
- the centrifuge bowl E1 has a rotor (not shown) having a blood storage space inside the collection, rotation driving means 14 for rotating the rotor, an inlet (first port E1a), and an outlet (second port E1b).
- the blood is separated into a plurality of blood components by the rotation of the rotor.
- the blood component separation circuit 1 stores a blood component separated by the centrifuge bowl E1, a first container (plasma bag) Y1, a second container (temporary storage bag) Y2, and a third container (platelet intermediate bag). Y3.
- the blood component separation circuit 1 has a first line, a second line, a third line, a fourth line, a fifth line, a sixth line, and a seventh line.
- the first line is for connecting the blood collection needle 2 and the centrifuge bowl E1, and from the donor tube T1, the first blood pump P1, the tube T2, the tube T3a, the first on-off valve V1, the tube T3b, and the tube T4. Composed.
- the second line is for connecting the centrifuge bowl E1 and the first container Y1, and includes a tube T5, a tube T6a, a second on-off valve V2, and a tube T6b.
- the third line is for connecting the first container Y1 and the first line.
- the fourth line is for connecting the centrifuge bowl E1 and the second container Y2, and includes a tube T5, a tube T15, a tube T11a, a fifth on-off valve V5, and a tube T11b.
- the fifth line is for connecting the second container Y2 and the first line, and includes a tube T12, a tube T13b, a sixth on-off valve V6, and a tube T13a.
- the sixth line is for connecting the second container Y2 and the first line in the same manner as the fifth line.
- the seventh line is for connecting the centrifuge bowl E1 and the third container Y3 and includes a tube T5, a tube T15, a tube T16, a tube T17a, an eighth on-off valve V8, and a tube T17b.
- a blood collection needle 2 which is a collection means for collecting whole blood (blood) from a donor, is connected to the first port of the first blood pump P1 by a donor tube T1.
- the first blood collection bag Y7 is connected to a blood collection needle through a first blood collection line 4 from a branch portion provided on the donor tube T1.
- the initial blood collection bag Y7 further includes a sampling port 3 for transferring the collected initial blood to a test container (not shown).
- the sampling port 3 includes a main body portion, a needle portion 6, and a cover portion 7 that covers the needle portion. Consists of. Further, a clamp 8 for opening and closing the line is provided on the initial blood collection line.
- the tube T2 connected to the second port of the first blood pump P1 is branched into two tubes T3a and T13a.
- the tube T3a is connected to the first port of the first on-off valve V1, and the first on-off valve V1 is connected to the first port.
- the 2 ports are connected to the tube T3b.
- the tube T3b is branched into two tubes T4 and T10a, and the tube T4 is connected to a first port E1a of a centrifuge bowl E1 that is a centrifuge for separating the collected blood into a plurality of blood components.
- the centrifuge bowl E1 is disposed on the rotation driving means 14 and is driven to rotate.
- the blood collection needle 2 and the first port E1a on the inlet side of the centrifuge bowl E1 are connected to the first line (donor tube T1, first blood pump P1, tube T2, tube T3a, first on-off valve V1, tube). T3b and tube T4) are connected.
- the pressure sensor C1 is connected to the donor tube T1.
- the tube T5 connected to the second port E1b of the centrifuge bowl E1 is branched into a tube T15 and a tube T6a.
- the tube T6a is connected to the first port of the second on-off valve V2, and the second port of the second on-off valve V2 is connected to the tube T6b.
- the tube T6b is connected to the second port Y1b of the plasma bag (first container) Y1.
- the second port E1b of the centrifuge bowl E1 and the plasma bag Y1 are connected by a second line (tube T5, tube T6a, second on-off valve V2, tube T6b). Note that there are two plasma bags Y1, which are omitted in FIGS.
- the first port Y1a on the output side of the plasma bag Y1 is connected to the tube T8a.
- the tube T8a is connected to the first port of the third on-off valve V3.
- the second port of the third on-off valve V3 is connected to the tube T8b, and the tube T8b is connected to the tube T9.
- the tube T9 is connected to the second port of the second blood pump P2.
- the first port of the second blood pump P2 is connected to the tube T10b, and the tube T10b is connected to the second port of the fourth on-off valve V4.
- the first port of the fourth on-off valve V4 is connected to the tube T10a.
- the tube T10a is connected to an intermediate position between the tube T3b and the tube T4 constituting the first line. That is, the plasma bag Y1 and the first line are connected by a third line (tube T8a, third on-off valve V3, tube T8b, tube T9, second blood pump P2, tube T10b, fourth on-off valve V4, tube T10a). It is connected. Thereby, the plasma bag Y1 is connected so as to selectively communicate with the inlet side or the outlet side of the centrifuge bowl E1.
- the tube T15 branched from the tube T5 is further branched into a tube T11a and a tube T16.
- the tube T11a is connected to the first port of the fifth on-off valve V5, and the second port of the fifth on-off valve V5 is connected to the tube T11b.
- the tube T11b connects to the second port Y2b of the temporary storage bag Y2. That is, the second port E1b of the centrifuge bowl E1 and the temporary storage bag Y2 are connected by the fourth line (tube T5, tube T15, tube T11a, fifth on-off valve V5, tube T11b).
- the first port Y2a of the temporary storage bag Y2 is connected to the tube T12 and branches into the tube T13b and the tube T14a.
- the tube T13b is connected to the first port of the sixth on-off valve V6, and the second port of the sixth on-off valve V6 is connected to the tube T13a.
- the tube T13a is connected to an intermediate position between the tube T2 and the tube T3a constituting the first line.
- the tube T14a branched from the tube T12 is connected to the first port of the seventh on-off valve V7, and the tube T14b is connected to the second port of the seventh on-off valve V7.
- the tube T14b is connected to an intermediate position between the tube T9 and the tube T8b, and the tube T9 is connected to the second port of the second blood pump P2.
- the first port of the second blood pump P2 is connected to the tube T10b, and the tube T10b is connected to the first port of the fourth on-off valve V4.
- the second port of the fourth on-off valve V4 is connected to the tube T10a.
- the tube T10a is connected to an intermediate position between the tube T3b and the tube T4 constituting the first line. That is, the temporary storage bag Y2 and the first line are the fifth line (tube T12, tube T13b, sixth open / close valve V6, tube T13a), and sixth line (tube T12, tube T14a, seventh open / close valve V7, Tube T14b, tube T9, second blood pump P2, tube T10b, fourth open / close valve V4, and tube T10a).
- Temporary storage bag Y2 is connected to selectively communicate with the inlet side or outlet side of centrifugal bowl E1.
- the tube T16 branched from the tube T15 is further branched into two tubes T17a and T18a.
- the tube T17a is connected to the first port of the eighth on-off valve V8, and the second port of the eighth on-off valve V8 is connected to the tube T17b.
- the tube T17b is connected to the first port Y3a on the input side of the platelet intermediate bag (third container) Y3.
- the tube T18a branched from the tube T16 is connected to the first port of the ninth on-off valve V9, and the second port of the ninth on-off valve V9 is connected to the tube T18b.
- the tube T18b is connected to the airbag Y4.
- the second port E1b of the centrifugal bowl E1 and the platelet intermediate bag Y3 are connected by a seventh line (tube T5, tube T15, tube T16, tube T17a, eighth on-off valve V8, tube T17b).
- the platelet intermediate bag Y3 is connected to communicate with the outlet side of the centrifuge bowl E1.
- a turbidity sensor C2 and a pressure sensor C3 for detecting the concentration of platelets are attached to a tube T5 connected to the second port E1b of the centrifugal bowl E1.
- the turbidity sensor C2 detects the degree to which the plasma passing through the tube T5 becomes turbid with platelets.
- an interface sensor C4 for detecting the interface position of the buffy coat layer BC (see FIG. 3) formed in the centrifugal bowl E1 is attached to the peripheral portion where the centrifugal bowl E1 is attached.
- the tube T20a is connected to the first port of the tenth on-off valve V10, and the tenth on-off
- the second port of the valve V10 is connected to the tube T20b.
- the tube T21 is connected to the first port that is the output side of the third blood pump P3.
- the second port on the input side of the third blood pump P3 is connected to the platelet preservation solution bottle by the bottle needle 10 via the sterilizing filter 9.
- the tube T20b is connected to the platelet bag Y5 via the leukocyte removal filter 11.
- an airbag Y6 is connected to the platelet bag Y5.
- the output port of the ACD pump P4 is connected in the middle of the donor tube T1.
- the input port of the ACD pump P4 is connected to the output port of the sterilization filter 12.
- the input port of the sterilization filter 12 is connected to the ACD storage bottle by the bottle needle 13.
- the control unit 15 is configured by, for example, a microcomputer, and includes a first blood pump P1, a second blood pump P2, a third blood pump P3, an ACD pump P4, and a centrifugal bowl drive device. 14, pressure sensor C1, turbidity sensor C2, pressure sensor C3, interface sensor C4, first on-off valve V1, second on-off valve V2, third on-off valve V3, fourth on-off valve V4, fifth on-off valve V5, first The sixth on-off valve V6, the seventh on-off valve V7, the eighth on-off valve V8, the ninth on-off valve V9, and the tenth on-off valve V10 are electrically connected.
- control unit 15 is electrically connected to a blood cell inspection device 32 (blood cell counting device) that measures a hematocrit value of blood. Further, the control unit 15 is electrically connected to a processing amount measuring means 34 for measuring a blood processing amount (blood collection amount).
- the detection signals from the sensors C1, C2, C3, and C4 are input to the control unit 15 as needed.
- the control unit 15 controls the operation / stop, rotation direction (forward / reverse rotation) and rotation speed of each pump P1, P2, P3, and P4 based on these detection signals and the like, and each on-off valve as necessary. Controls the opening / closing of V1, V2, V3, V4, V5, V6, V7, V8, V9, V10 and the operation of the centrifugal bowl drive device 14. Further, hematocrit value (HCT value) measurement result data by the blood cell test device 32 and blood processing amount measurement result data by the processing amount measuring means 34 are input to the control unit 15 as needed.
- the control unit 15 also serves as “calculation means” in the present invention.
- constituent material of the tube examples include various thermoplastic elastomers such as polyvinyl chloride, polyethylene, polypropylene, polyester such as PET and PBT, ethylene-vinyl acetate copolymer (EVA), polyurethane, and polyester elastomer.
- polyvinyl chloride is particularly preferred.
- Polyvinyl chloride provides sufficient flexibility and flexibility, is easy to handle, and is suitable for clogging with a clamp or the like.
- a polymer obtained by polymerizing or copolymerizing olefin or diolefin such as soft polyvinyl chloride, polyolefin, ethylene, propylene, butadiene, and isoprene in which DEHP is used as a plasticizer
- olefin or diolefin such as soft polyvinyl chloride, polyolefin, ethylene, propylene, butadiene, and isoprene in which DEHP is used as a plasticizer
- EVA ethylene-vinyl acetate copolymer
- PET, PBT, PCGT, etc. can be used.
- polyvinyl chloride is particularly preferable.
- a container having excellent gas permeability is preferable for a container for storing platelet liquid, such as polyolefin and DnDP plasticized polyvinyl chloride. It is preferable to use a sheet having a reduced thickness.
- FIG. 3 shows the structure of the centrifuge bowl E1.
- the right side of the center line is a cross-sectional view, and the left side is a dotted line showing an external view.
- an inflow port E1a and an outflow port E1b are formed in the fixed portion 20, which is a fixed portion that does not rotate.
- a cover 17 and an inflow pipe 18 extending downward are connected to the fixed portion 20.
- the side wall 21, the outer shell 22, the inner shell 23, and the bottom plate 16 are rotatably held integrally with these fixed portions.
- the bottom plate 16 is adsorbed by the centrifugal bowl driving device 14 and is given a rotational force by the centrifugal bowl driving device 14.
- FIG. 3 shows a state in which whole blood is supplied from the inflow port E1a into the centrifuge bowl E1 and blood components are separated by centrifugal force.
- the red blood cell layer RBC, the white blood cell layer WBC, the buffy coat layer BC, the platelet layer PLT, and the plasma layer PPP are formed by the centrifugal force in descending order of specific gravity.
- the white blood cell layer WBC and the platelet layer PLT are close in specific gravity, they are difficult to separate. Therefore, there exists a buffy coat layer BC including a white blood cell layer WBC and a platelet layer PLT.
- the breakdown of whole blood is about 55% for plasma PPP, about 43.2% for red blood cell RBC, about 1.35% for white blood cell WBC, and about 0.45% for platelet PLT.
- the outflow passage 19 formed slightly above the midpoint of the inflow pipe 18 is formed in the inner peripheral portion, it is formed in the inner periphery in the space formed by the outer shell 22 and the side wall 21. It flows out of the centrifuge bowl E1 through the outlet E1b from the plasma layer PPP.
- FIGS. 4 and 5 are flowcharts, and FIGS. 6 to 18 illustrate the operation and process of the blood component separation device.
- the purpose of this device is to collect high-concentration platelet fluid.
- FIG. 19 shows the operation / action of the blood component separation device in a time series as a process diagram.
- FIG. 6 is a diagram showing a blood collection start process (first process).
- a white display indicates an operating state
- a black display indicates a stopped state.
- a white display indicates an open state
- a black display indicates a closed state.
- the priming step (S1) in FIG. 4 is performed.
- the ACD pump P4 and the first pump P1 are driven, and ACD liquid for preventing blood coagulation is supplied to the centrifugal bowl E1 through the opened first on-off valve V1, and the centrifugal bowl E1 and the first A priming step (S1) for the pump P1 and the like is performed.
- the priming is a process in which an ACD solution is previously attached to a portion that comes into contact with blood such as in the donor tube T1, the first pump P1, and the centrifuge bowl E1 so that the blood does not coagulate when flowing. From the priming process, the centrifuge bowl drive device 14 rotates the centrifuge bowl E1 at a predetermined rotation speed.
- the blood collection needle 2 is punctured into the blood donor and the collection of whole blood is started (S2).
- the blood donor 2 is punctured into the blood donor, and then the primary blood is collected in the primary blood collection bag Y7 (see FIG. 1) in the primary blood collection circuit.
- the branch portion provided on the donor tube T1 is initially configured to connect the blood collection needle 2 and the initial blood collection line 4 (see FIG. 1).
- the initial blood collection line 4 is closed by the clamp 8 (see FIG. 1), and a flow path on the first blood pump P1 side of the donor tube T1 is secured.
- the ACD pump P4 is driven, the ACD liquid is supplied to the donor tube T1, mixed with the whole blood, and the whole blood is supplied to the centrifuge bowl E1.
- whole blood is supplied to the rotating centrifuge bowl E1, it is pushed by the plasma from the outflow passage 19 (see FIG. 3) located in the inner peripheral portion of the centrifuge bowl E1, and as shown in FIG.
- the air in the bowl E1 (shown by a dotted line) flows out.
- the air that has flowed out is stored in the airbag Y4 through the opened ninth on-off valve V9.
- the whole blood is separated into each component by applying a centrifugal force to the supplied whole blood in the bowl.
- the third on-off valve V3 is opened to drive the second blood pump P2.
- the fourth open / close valve V4 is opened to collect the whole blood from the donor, and the plasma stored in the plasma bag Y1 is mixed with the whole blood and supplied to the centrifugal bowl E1.
- the current cycle is the final cycle. If the current cycle is not the final cycle (S7: NO), the sixth open / close valve V6 is opened, the state where the first blood pump P1 is driven is maintained, and the temporary storage bag The collected whole blood is stored in Y2 (S11). In other words, the collection of whole blood is continued by storing the whole blood collected in the temporary storage bag Y2. The whole blood is continuously collected until the circulation / acceleration process is completed or until a predetermined amount of time is reached. In the case of the final cycle (S7: YES), the first blood pump P1 is stopped and blood collection is stopped (S8).
- the circulation rate is made faster than the critical flow step, and plasma is passed through the centrifuge bowl E1 at a rate of about 100 ml / min for about 30 to 40 seconds. Circulate.
- the particulate matter concentration in the buffy coat layer BC in FIG. 3 is reduced, and the white blood cell layer WBC having a higher specific gravity than the platelets is deposited outside the buffy coat layer BC. That is, the platelet layer PLT and the leukocyte layer WBC can be more clearly separated.
- the process enters the acceleration process (fifth process) in the circulation / acceleration process shown in FIG.
- the acceleration process by controlling the rotation speed of the second blood pump P2, the rotation speed is gradually increased and the plasma flow rate is sequentially increased.
- the flow rate is increased starting from 100 ml / min, and the plasma flow rate is accelerated until platelets flow out.
- This is the acceleration period TG shown in FIG.
- the circulation process and the acceleration process are combined and expressed as a circulation / acceleration process (S9, S12).
- the platelet PLT gains a force in the ascending direction and is released from the outflow passage 19 to the outside of the centrifugal bowl E1.
- the white blood cell layer WBC and the red blood cell layer RBC having large specific gravity do not leave the outflow passage 19 because the centrifugal force is stronger.
- FIG. 20 shows changes in the concentration of platelets, white blood cells, and red blood cells flowing out.
- the horizontal axis is the time course at the time of platelet collection, and the vertical axis is the concentration of the blood cell component that flows out.
- TA platelet outflow
- the amount of platelet outflow increases gradually, and gradually decreases when the maximum flow rate is exceeded.
- leukocytes gradually increase in outflow and decrease gradually after the maximum flow rate.
- FIG. 5 Details of S9 and S12 are shown in FIG. 5 as a flowchart showing the operation of the blood component separation device.
- the platelet outflow period TA includes a low concentration period TB in which low-concentration platelet liquid flows out first, followed by a high concentration period TC in which high-concentration platelet liquid outflows, and then the low-concentration platelet liquid again. It can be divided into low concentration periods TD that flow out. Here, in order to obtain a high concentration platelet solution, a low concentration platelet solution is unnecessary.
- the second on-off valve V2 is closed.
- the fifth on-off valve V5 is opened, and the platelet solution of the low concentration period TB of FIG. 20 is stored in the temporary storage bag Y2 (S22).
- the low-concentration platelet liquid is stored in the temporary storage bag Y2 in a state of being mixed with the whole blood.
- the first blood pump P1 is kept in a driving state, and the whole blood collected from the blood donor continues to be stored in the temporary storage bag Y2.
- the temporary storage bag Y2 is used as a buffy coat bag simultaneously with the whole blood bag.
- the turbidity sensor C2 detects that the platelet liquid has a high concentration, it is determined that it is a TC period (S23: YES), and the fifth on-off valve V5 is closed as shown in FIG. Then, the eighth on-off valve V8 is opened. Thereby, the high-concentration platelet liquid that flows out during the high-concentration period TC can be stored in the platelet intermediate bag Y3 (S24).
- the platelet intermediate bag Y3 when a predetermined amount of high-concentration platelet liquid is stored in the platelet intermediate bag Y3, it is determined that it is a TD period (S25: YES), and as shown in FIG. 12, the platelet intermediate bag Y3 Therefore, the eighth on-off valve V8 is closed and the fifth on-off valve V5 is opened. Thereby, the low-concentration platelet liquid flowing out during the low-concentration period TD can be stored again in the temporary storage bag Y2 (S26).
- the amount of the high-concentration platelet liquid stored in the platelet intermediate bag Y3 can be easily adjusted by controlling the valve opening time of the eighth on-off valve V8 based on the flow rate of the platelet liquid flowing out from the centrifugal bowl E1. Can do.
- the rotation of the centrifugal bowl E1 is stopped, the sixth on-off valve V6 and the fifth on-off valve V5 are closed, the first on-off valve V1 and the ninth on-off valve V9 are opened, and the first blood pump P1 is reversely rotated.
- the blood return to return the blood remaining in the centrifuge bowl E1 to the donor is started.
- the reverse rotation speed of the first blood pump P1 is driven at a double speed of the normal rotation speed to shorten the blood return time.
- the second blood pump P2 is driven to return the plasma that has been collected too much and stored in the plasma bag Y1.
- the blood stored in the temporary storage bag Y2 also opens the seventh on-off valve V7, drives the second blood pump P2, and simultaneously flows into the centrifuge bowl E1 through the fourth on-off valve V4 (S14). ).
- the third on-off valve V3 is closed so that the fluid does not flow into the plasma bag Y1.
- the ninth on-off valve V9 is closed and the second on-off valve V2 is opened.
- the plasma overflowing from the centrifugal bowl E1 is stored in the plasma bag Y1.
- FIG. (Same state), the state in which the second blood pump P2 is driven is maintained, the seventh on-off valve V7 is closed, and the plasma stored in the plasma bag Y1 is mixed with the whole blood and supplied to the centrifuge bowl E1.
- the third on-off valve V3 is opened, and the plasma critical flow process is started.
- FIG. 9 (circulation process) is continued.
- This cycle is usually performed for 3 or 4 cycles until a predetermined amount of platelet PLT is secured.
- blood is collected in parallel during the circulation period TF2 and acceleration period TG2 of the second cycle, and whole blood is stored in the temporary storage bag Y2.
- the blood in the temporary storage bag Y2 is mixed with whole blood and supplied to the centrifuge bowl E1.
- blood is not collected during the circulation period TF3 and the acceleration period TG3. This is because there is no fourth cycle.
- the blood collection needle 2 is removed from the blood donor, and the blood collection is completed.
- high-concentration platelet liquid stored in the platelet intermediate bag Y3 is injected into the platelet bag Y5.
- the platelet preservation solution remaining in the platelet preservation solution bottle is injected into the platelet bag Y5 by the bottle needle 10 connected to the platelet preservation solution bottle.
- the correction function for the measured value of the HCT value measured by the blood cell test apparatus 32 is automated, and a predetermined arithmetic expression is used based on the corrected HCT value per cycle in the platelet fluid sampling operation.
- the predicted extracorporeal circulation amount is calculated as the amount of blood collected (blood processing amount).
- the measured value of the HCT value measured by the blood cell test apparatus 32 may cause an error from the actual HCT value.
- the predicted extracorporeal circulation amount which is a target blood collection amount per cycle calculated based on the measured value of the HCT value by the control unit 15 and one cycle actually measured by the processing amount measuring means 34.
- the blood component separation circuit 1 cannot collect a target concentration of platelet fluid (target platelet count) due to an error with the amount of processed blood.
- the control unit 15 uses the data value A of the predicted extracorporeal circulation amount in a plurality of platelet fluid collection operations immediately after the platelet fluid collection operation has been completed, and the platelet fluid collection operation already.
- the control part 15 correct
- the control part 15 performs the calculation process of such an estimated extracorporeal circulation amount by collection operation of each time platelet liquid.
- the true HCT correction value ⁇ is specifically obtained based on the following equation.
- the current HCT correction value is ⁇ 0
- the predicted extracorporeal circulation amount data value is A
- the blood treatment amount data value actually measured in the first cycle is B.
- the current HCT correction value ⁇ 0 is a correction value that is currently set as an HCT correction value (a correction value for the measured value of the HCT value measured by the blood cell examination device 32).
- the data value A of the predicted extracorporeal circulation amount is the average value of the data values of the predicted extracorporeal circulation amount in the plurality of platelet fluid sampling operations most recently after the completion of the platelet fluid sampling operation.
- the data value B of the blood processing amount actually measured in the first cycle was actually measured in the first cycle in the plurality of platelet fluid sampling operations immediately after the platelet fluid sampling operation was completed. Let it be the average of the data values of the blood throughput.
- the data value A of the predicted extracorporeal circulation amount and the data value B of the blood processing amount actually measured in the first cycle are updated as needed every time one platelet fluid collection operation is completed. . Therefore, the true HCT correction value ⁇ is updated as needed in each round of platelet fluid collection operations. Therefore, the predicted extracorporeal circulation amount can be accurately calculated according to the measurement accuracy of the HCT value of the blood cell test apparatus 32.
- each data value in the most recent platelet fluid sampling operation is the data value when blood sampling was interrupted before the platelet fluid sampling operation was completed (data value of the intermediate suspension example). It is desirable that the data value be created.
- Each data value in the most recent platelet fluid sampling operation may be, for example, each data value in the latest 50 platelet fluid sampling operations, but is not particularly limited to this.
- Each data value in the platelet fluid collection operation of less than 50 times (for example, each data value in the latest 10 to 20 platelet fluid collection operations) may be used.
- n indicates the number of sampling operations, and indicates an example of data in the first cycle (indicated as “cycle1” in the figure) and the second cycle (indicated as “cycle2” in the figure).
- control unit 15 corrects the measured value of the HCT value measured by the blood cell test apparatus 32 using the true HCT correction value ⁇ , and calculates the corrected HCT value. Then, based on the calculated corrected HCT value, a predicted external circulation amount in the current sampling operation is calculated by a predetermined arithmetic expression.
- control unit 15 automatically corrects the measured value of the HCT value measured by the blood cell test apparatus 32, and substitutes the corrected HCT value into a predetermined arithmetic expression to perform prediction. Calculate extracorporeal circulation volume.
- the HCT correction value may be calculated for each centrifugal condition including the centrifugal rotation speed.
- the blood component separation device may be provided with a function for turning on and off the correction function of the HCT value.
- the predicted extracorporeal circulation amount that is predicted as the target blood collection amount per cycle in the platelet fluid collection operation is measured by the blood cell test device 32.
- the controller 15 calculates the HCT value after correcting the measured value of the HCT value.
- the control unit 15 sets the true HCT correction value ⁇ to be used when correcting the measured value of the HCT value in a plurality of platelet fluid sampling operations immediately before the platelet fluid sampling operation has been completed.
- the true HCT correction value ⁇ is calculated based on the data values in the most recent platelet fluid sampling operations, and the measured value of the HCT value is corrected by the calculated true HCT correction value ⁇ .
- the correction for the measured value of the HCT value automatically corresponds to the measurement accuracy of the blood cell examination device 32 after calibration by the blood component separation device.
- the accuracy of the predicted extracorporeal circulation amount calculated can be improved. Therefore, regardless of the measurement accuracy of the HCT value in the blood cell test apparatus 32, a platelet solution having a target concentration can be collected.
- the data value A of the predicted extracorporeal circulation amount in the most recent platelet fluid sampling operation and the data value B of the blood sample measured in the first cycle in the most recent platelet fluid sampling operation are: It is created by deleting the data value when blood collection was stopped halfway before the completion of the platelet fluid collection operation.
- the true HCT correction value ⁇ is calculated by citing only the data value in the collection operation in which the platelet fluid could actually be collected.
- a centrifuge step in which whole blood collected from a blood donor is introduced into the centrifuge bowl E1 and separated into a plurality of blood components; b) the centrifuge blood Among the predetermined blood components separated by centrifugation, a circulation flow step of introducing plasma together with whole blood into the centrifuge bowl E1, and c) after separation of a predetermined amount of plasma in the circulation flow step.
- the supply of whole blood to the centrifuge is stopped, only plasma is introduced into the centrifuge, and the blood is further circulated for a predetermined time, and then the circulation speed is accelerated to remove the platelet liquid by the centrifuge.
- the circulation / acceleration step includes a first collection step of transferring a low concentration of platelet liquid to a temporary storage container, and among the platelet liquid, A second collecting step for collecting high-concentration platelet liquid, and the low-concentration platelet liquid transferred to the temporary storage container is introduced into the centrifuge bowl E1 together with whole blood collected in the next cycle.
- BC recycling ffy coat recycling
- Example 2 Next, the second embodiment will be described.
- the same components as those of the first embodiment are denoted by the same reference numerals, the description thereof will be omitted, and different points will be mainly described.
- the blood component separation apparatus according to the second embodiment is different from the blood component separation apparatus according to the first embodiment in that BC recycling is not mainly used.
- the system configuration of the blood component separation apparatus of Example 2 is shown in FIG.
- the blood component separation circuit 30 according to the second embodiment does not have the temporary storage bag Y2 as a main point different from the first embodiment.
- FIG. 23 is a flowchart showing the operation of the blood component separation device
- FIGS. 24 to 26 show the operation and process of the blood component separation device.
- the blood component separation device of Example 2 performs the priming process as in Example 1 (S101).
- the collection of whole blood is started and the centrifugation is started (S102, first blood collection step).
- the ninth on-off valve V9 is closed, the second on-off valve V2 is opened, and the plasma overflowing from the centrifugal bowl E1 is stored in the plasma bag Y1.
- the first on-off valve V1 is closed as shown in FIG. V3 is opened and the plasma is returned to the centrifuge bowl E1 (S104, first circulation step).
- the first on-off valve V1 is opened, the collection of whole blood is resumed, and the blood is introduced into the centrifuge bowl E1 (S105, second blood collection step).
- the first opening / closing operation is performed as in the first circulation step.
- the valve V1 is closed, the collection of whole blood is temporarily stopped, the third on-off valve V3 is opened, and the plasma is returned to the centrifuge bowl E1 (S107, second circulation step).
- the circulation rate is increased from 60 ml / min to 170-200 ml / min.
- the first on-off valve V1 is opened to resume the collection of whole blood, and in order to make the collection of platelet liquid more reliable, the blood collection amount automatically calculated according to the HCT value is collected (S108, Third blood collection step).
- the first on-off valve V1 is closed to suspend the collection of whole blood and perform circulation to return the plasma to the centrifugal bowl E1, but gradually accelerate the circulation speed (S109, acceleration step).
- the circulation rate is increased from 60 ml / min to 150 ml / min, and finally increased to 200 ml / min.
- the platelet liquid stored in the platelet intermediate bag Y3 is injected into the platelet bag Y5 through the leukocyte removal filter 11, and thereafter the platelets Seal the two tubes of the bag. Thereby, the platelet bag Y5 in which the high-concentration platelet liquid is stored is completed. Thereby, all the processes are completed. If it is not the last cycle (S112: NO), the process returns to the first blood collection step (S102) again.
- control unit 15 also stores data values in a plurality of sampling operations most recently after the platelet liquid sampling operation has been completed.
- the true HCT correction value ⁇ it is possible to collect a platelet solution having a target concentration regardless of the measurement accuracy of the HCT value in the blood cell test apparatus 32.
- the buffy coat bag and the whole blood bag are used in the temporary storage bag Y2, but the buffy coat bag and the whole blood bag may be provided in parallel as separate bags.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- External Artificial Organs (AREA)
Abstract
Description
実施例1の血液成分分離装置のシステム構成を図1に示す。図2は、実施の形態に係る血液成分分離装置の制御系を示すブロック図である。
[数1]
α=α0×(A/B)
次に、実施例2について説明するが、実施例1と同等の構成要素については、同一の符号を付して説明を省略し、異なった点を中心に述べる。実施例2の血液成分分離装置は、主にBCリサイクルを用いない点で実施例1の血液成分分離装置と異なる。ここで、実施例2の血液成分分離装置のシステム構成を図22に示す。実施例2の血液成分分離回路30は、実施例1と異なる主な点として、一時貯留バッグY2を有していない。
9 除菌フィルタ
10 瓶針
15 制御部
30 血液成分分離回路
32 血球検査装置
34 処理量測定手段
E1 遠心ボウル
Y1 血漿バッグ(第1の容器)
Y2 一時貯留バッグ(第2の容器)
Y3 血小板中間バッグ(第3の容器)
Y4 エアバッグ
Y5 血小板バッグ
Y6 エアバッグ
C2 濁度センサ
C4 界面センサ
P1 第1血液ポンプ
P2 第2血液ポンプ
P3 第3血液ポンプ
V1 第1開閉弁
V2 第2開閉弁
V3 第3開閉弁
V4 第4開閉弁
V5 第5開閉弁
V6 第6開閉弁
V7 第7開閉弁
V8 第8開閉弁
V9 第9開閉弁
V10 第10開閉弁
T1~21 チューブ
Claims (5)
- 血液から所定の複数の血液成分を分離するための遠心分離器と、遠心分離した所定の血液成分を収容する容器を備え、該分離された前記所定の血液成分を採取する工程を複数サイクル行う血液成分分離装置において、
前記所定の血液成分の採取操作における1サイクル当たりの目標の採血量として予測される予測体外循環量を、血球検査装置で測定したヘマトクリット値の測定値に対して補正を行った後のヘマトクリット値をもとに算出する演算手段を有し、
前記演算手段は、前記補正を行うときに使用する補正値を、既に前記採取操作が終了した直近の複数回の前記採取操作における前記予測体外循環量のデータ値と、前記直近の複数回の前記採取操作における第1サイクル目にて実測された採血量のデータ値とをもとに算出すること、
を特徴とする血液成分分離装置。 - 請求項1の血液成分分離装置において、
前記予測体外循環量のデータ値と前記第1サイクル目にて実測された採血量のデータ値は、前記採取操作が終了する前に採血を途中で中止したときのデータ値を削除して作成されたものであること、
を特徴とする血液成分分離装置。 - 請求項1または2の血液成分分離装置において、
a)供血者から採取した全血を遠心分離器に導入し、複数の血液成分に分離する遠心分離工程と、
b)遠心分離された血液成分のうち、前記遠心分離により分離された所定の血液成分のうち、第1の血液成分を前記遠心分離器内に全血と共に導入する循環フロー工程と、
c)前記循環フロー工程にて、所定量の前記第1の血液成分を分離後、全血の前記遠心分離器への供給を停止して、前記遠心分離器に第1の血液成分のみを導入し、所定時間さらに循環させた後、循環速度を加速することにより第2の血液成分を前記遠心分離器により分離し、採取する循環・加速工程と、
d)前記循環・加速工程において、所定量の第2の血液成分を採取後、採取しなかった血液成分について供血者へ返血する返血工程と、を有し、
前記a)~d)の工程を1サイクルとして、該サイクルを複数回行うこと、
を特徴とする血液成分分離装置。 - 請求項3の血液成分分離装置において、
前記循環・加速工程は、
第2の血液成分のうち、低濃度の第2の血液成分を一時貯留容器に移送する第1の採取工程と、
第2の血液成分のうち、高濃度の第2の血液成分を採取する第2の採取工程と、を含み、
前記一時貯留容器に移送された低濃度の第2の血液成分は、次サイクルにおいて採取された全血と併せて前記遠心分離器に導入されること、
を特徴とする血液成分分離装置。 - 請求項1の血液成分分離装置において、
前記所定の血液成分は、血小板液であること、
を特徴とする血液成分分離装置。
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201380071500.8A CN104955497B (zh) | 2013-02-26 | 2013-02-26 | 血液成分分离装置 |
| PCT/JP2013/054881 WO2014132327A1 (ja) | 2013-02-26 | 2013-02-26 | 血液成分分離装置 |
| EP13876722.3A EP2962709B1 (en) | 2013-02-26 | 2013-02-26 | Blood component separation apparatus |
| US14/769,966 US20150367063A1 (en) | 2013-02-26 | 2013-02-26 | Blood Component Separation Apparatus |
| JP2015502595A JP5980410B2 (ja) | 2013-02-26 | 2013-02-26 | 血液成分分離装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2013/054881 WO2014132327A1 (ja) | 2013-02-26 | 2013-02-26 | 血液成分分離装置 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014132327A1 true WO2014132327A1 (ja) | 2014-09-04 |
Family
ID=51427632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2013/054881 Ceased WO2014132327A1 (ja) | 2013-02-26 | 2013-02-26 | 血液成分分離装置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150367063A1 (ja) |
| EP (1) | EP2962709B1 (ja) |
| JP (1) | JP5980410B2 (ja) |
| CN (1) | CN104955497B (ja) |
| WO (1) | WO2014132327A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112003B2 (en) | 2012-03-27 | 2018-10-30 | Terumo Kabushiki Kaisha | Blood component separation device |
| TWI725676B (zh) * | 2018-12-25 | 2021-04-21 | 日商旭化成醫療股份有限公司 | 具備血液淨化裝置與血液成分調整器的體外血液循環系統 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11386993B2 (en) | 2011-05-18 | 2022-07-12 | Fenwal, Inc. | Plasma collection with remote programming |
| US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
| WO2015095794A1 (en) | 2013-12-20 | 2015-06-25 | Advanced ReGen Medical Technologies, LLC | Compositions for cellular restoration and methods of making and using same |
| US10828415B2 (en) * | 2015-06-19 | 2020-11-10 | Mallinckrodt Hospital Products IP Limited | Devices, methods, and systems for priming, separating, and collecting blood components |
| JP6999575B2 (ja) | 2016-04-29 | 2022-01-18 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | マイクロrna組成物並びにその作製及び使用方法 |
| PL3512577T3 (pl) | 2016-09-16 | 2025-07-14 | Fenwal, Inc. | Układy separacji krwi wykorzystujące techniki separacji odśrodkowej i separacji z użyciem wirującej membrany |
| US11412967B2 (en) | 2018-05-21 | 2022-08-16 | Fenwal, Inc. | Systems and methods for plasma collection |
| KR102345761B1 (ko) | 2018-05-21 | 2022-01-03 | 펜월, 인크. | 혈장 수집 체적의 최적화를 위한 시스템 |
| US12033750B2 (en) | 2018-05-21 | 2024-07-09 | Fenwal, Inc. | Plasma collection |
| EP4483917A3 (en) | 2019-03-05 | 2025-03-19 | Fenwal, Inc. | Collection of mononuclear cells and peripheral blood stem cells |
| EP3705147B1 (en) | 2019-03-05 | 2024-11-06 | Fenwal, Inc. | Collection, genome editing, and washing of t-cell lymphocytes |
| AU2020241371A1 (en) * | 2019-03-18 | 2021-10-07 | Advanced ReGen Medical Technologies, LLC | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment |
| EP3741460B1 (en) | 2019-05-23 | 2023-09-27 | Fenwal, Inc. | Adjustment of target interface location between separated fluid components in a centrifuge |
| EP4566642A1 (en) | 2019-05-23 | 2025-06-11 | Fenwal, Inc. | Centrifugal separation and collection of red blood cells or both red blood cells and plasma |
| EP4000665B1 (en) | 2019-09-16 | 2023-04-19 | Fenwal, Inc. | Dynamic adjustment of algorithms for separation and collection of blood components |
| EP3834858A1 (en) | 2019-12-12 | 2021-06-16 | Fenwal, Inc. | Systems enabling alternative approaches to therapeutic red blood cell exchange and/or therapeutic plasma exchange |
| CN111529791B (zh) * | 2020-05-08 | 2022-11-29 | 四川天府亨特生命科技有限公司 | 可减少采集血浆中白细胞混入量的方法及血浆采集系统 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09313599A (ja) * | 1996-02-22 | 1997-12-09 | Haemonetics Corp | 適応型アフェレーシス装置 |
| JP2907689B2 (ja) * | 1992-07-10 | 1999-06-21 | コウブ ラボラトリーズ,インコーポレーテッド | 血液成分の産出物を得る方法および装置 |
| JP3196838B2 (ja) * | 1998-09-11 | 2001-08-06 | ヘモネティクス・コーポレーション | アフェレーシス装置及び血液製剤の製造方法 |
| JP2002291872A (ja) * | 2001-03-28 | 2002-10-08 | Terumo Corp | 血液成分採取装置 |
| JP3936132B2 (ja) * | 2000-10-27 | 2007-06-27 | テルモ株式会社 | 血小板採取装置 |
| JP2009226210A (ja) | 2008-02-29 | 2009-10-08 | Haemonetics Corp | アフェレーシス装置 |
| JP4848125B2 (ja) * | 2004-10-28 | 2011-12-28 | テルモ株式会社 | 血液成分採取装置および血液成分採取システム |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014041599A1 (ja) * | 2012-09-11 | 2014-03-20 | テルモ株式会社 | 血液成分分離装置 |
-
2013
- 2013-02-26 WO PCT/JP2013/054881 patent/WO2014132327A1/ja not_active Ceased
- 2013-02-26 US US14/769,966 patent/US20150367063A1/en not_active Abandoned
- 2013-02-26 CN CN201380071500.8A patent/CN104955497B/zh active Active
- 2013-02-26 EP EP13876722.3A patent/EP2962709B1/en active Active
- 2013-02-26 JP JP2015502595A patent/JP5980410B2/ja active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2907689B2 (ja) * | 1992-07-10 | 1999-06-21 | コウブ ラボラトリーズ,インコーポレーテッド | 血液成分の産出物を得る方法および装置 |
| JPH09313599A (ja) * | 1996-02-22 | 1997-12-09 | Haemonetics Corp | 適応型アフェレーシス装置 |
| JP3196838B2 (ja) * | 1998-09-11 | 2001-08-06 | ヘモネティクス・コーポレーション | アフェレーシス装置及び血液製剤の製造方法 |
| JP3936132B2 (ja) * | 2000-10-27 | 2007-06-27 | テルモ株式会社 | 血小板採取装置 |
| JP2002291872A (ja) * | 2001-03-28 | 2002-10-08 | Terumo Corp | 血液成分採取装置 |
| JP4848125B2 (ja) * | 2004-10-28 | 2011-12-28 | テルモ株式会社 | 血液成分採取装置および血液成分採取システム |
| JP2009226210A (ja) | 2008-02-29 | 2009-10-08 | Haemonetics Corp | アフェレーシス装置 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112003B2 (en) | 2012-03-27 | 2018-10-30 | Terumo Kabushiki Kaisha | Blood component separation device |
| TWI725676B (zh) * | 2018-12-25 | 2021-04-21 | 日商旭化成醫療股份有限公司 | 具備血液淨化裝置與血液成分調整器的體外血液循環系統 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150367063A1 (en) | 2015-12-24 |
| EP2962709A4 (en) | 2016-10-26 |
| JP5980410B2 (ja) | 2016-08-31 |
| CN104955497A (zh) | 2015-09-30 |
| EP2962709A1 (en) | 2016-01-06 |
| CN104955497B (zh) | 2017-03-15 |
| JPWO2014132327A1 (ja) | 2017-02-02 |
| EP2962709B1 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5980410B2 (ja) | 血液成分分離装置 | |
| JP6542781B2 (ja) | 血液成分分離装置 | |
| JP5863978B2 (ja) | 血液成分分離装置 | |
| JP6157451B2 (ja) | 血液成分分離装置 | |
| JP6097758B2 (ja) | 血液成分分離装置 | |
| JP6081448B2 (ja) | 血液成分分離装置 | |
| WO2014102888A1 (ja) | 血液成分分離装置 | |
| JP6010607B2 (ja) | 血液成分分離装置 | |
| JP6333348B2 (ja) | 血液成分分離装置および血液成分分離方法 | |
| JP6173861B2 (ja) | 血液成分分離装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13876722 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2015502595 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14769966 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013876722 Country of ref document: EP |